CTRI/2024/04/065020招募中4 期
A Double-blind, Randomized, Placebo-Controlled, Comparative Study for Assessing the Efficacy and Safety of ParActin® in Individuals with Upper respiratory tract infections - Nil
试验速览
- 阶段
- 4 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male and female aged between 18 and 50 years as of the screening date.
- •2. Individuals with symptoms of acute upper respiratory tract infection as assessed by the investigator at the time of screening.
- •3. BMI = 29.9 kg/m2.
- •4. Upper respiratory tract infection symptoms present for at least 24 hours but not more than 48 hours prior to screening visit.
- •5. Those having a score of = 5 for at least 2 symptoms out of runny nose, plugged nose, sneezing or sore throat, on the WURSS-21.
- •6. History of frequent common cold with past episode duration of at least 4 days.
- •7. Must be literate and have the ability to complete the study-based questionnaires and requirements.
排除标准
- •High grade fever defined as body temperature = 39ºC (= 102.2 ºF)
- •2. With a history of allergy (allergic rhinitis) along with symptoms such as sneezing, runny nose and red, watery and itchy eyes.
- •3. Individuals with history of Chronic obstructive pulmonary disease, pulmonary fibrosis or Asthma.
- •4. Individuals with rhinitis medicamentosa, chronic cough of bacterial, fungal or other known origin.
- •5. Individuals requiring hospitalization or likely to be hospitalised due to URTI.
- •6. Individuals with common cold for the first time.
- •7. Individuals with anatomical nasal obstruction/ deformity or nasal reconstructive surgery etc
- •8. Individuals with history of heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies
- •9. Individuals with history of immunocompromised state immune system with/ without organ transplant
- •10. Individuals with known or suspected hypersensitivity or intolerance to herbal products
- •11. Individuals diagnosed with Sickle cell disease, Thalassemia, Type I/ II Diabetes mellitus, Cystic fibrosis
- •12. Diagnosed cases of Uncontrolled hypertension as assessed by a systolic blood pressure = to 140mmHg and diastolic blood pressure = to 90mmHg
- •13. Those not willing to abstain from home based cold remedies that include but are not limited to steam inhalation, decoctions, vapour rub, ginger supplement, decoctions, or any form of dietary and/or herbal supplements during the entirety of study participation period.
- •14. Those who have been vaccinated for influenza, swine flu 3 months prior to screening visit
- •Those who have taken within one week of the start of the study or require during study antibiotics, antivirals, steroids, nasal decongestants, antihistamines herbal remedies, Vitamin C or Zinc to alleviate cold symptoms.
- •16. Those who have severe mental illnesses, such as dementia, Parkinson’s disease, Alzheimer’s Disease, depression or anxiety disorders, or those who are currently taking psychoneurological drugs, such as antidepressants.
- •17. Those who have participated in other clinical study within 30 days, prior to the screening visit or plan to participate in other clinical study during the study period.
- •18. Individuals with substance abuse as per last two-year history that includes the use of but is not limited to drugs such as cocaine, amphetamine, marijuana etc.
- •19. Individuals having a history of smoking or currently smoking or using any form of smokeless tobacco.
- •20. Individuals with heavy alcohol consumption, defined as:
- •a) For men: More than 14 standard alcoholic drink (SAD)/week or more than 4 SAD in a day.
- •b) For women: More than 7 SAD/week or more than 3 SAD in a day.
- •c) Binge drinkers, defined as 5 or more SAD for men, in a 2-hour time frame
- •d) Binge drinkers, defined as 4 or more SAD for Women, in a 2 hour time frame.
- •(NOTE A standard alcoholic drink contains approximately 14 grams of alcohol, which is equivalent to 12 ounces of beer (5 per alcohol), 8.5 ounces of malt liquor (9 per alcohol), 5 ounces of wine (12 per alcohol), 3.5 ounces of fortified wine (example sherry or port), or 1.5 ounces of liquor (distilled spirits 40 per alcohol)
- •21. Those who have clinically significant disorder of cardiovascular, endocrine, lymphatic, respiratory, hepatobiliary, urinary, reproductive, central nervous system, musculoskeletal an
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of FractureOsteoporosis in postmenopausal womenMedDRA version: 16.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-022576-30-CZRadius Health, Inc.2,400
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of FractureOsteoporosis in postmenopausal womenMedDRA version: 14.1Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-022576-30-LTRadius Health, Inc.2,400
进行中（未招募）
1 期
A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of FractureOsteoporosis in postmenopausal womenMedDRA version: 14.1Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-022576-30-DKRadius Health, Inc.2,400
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of FractureOsteoporosis in postmenopausal womenMedDRA version: 17.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-022576-30-PLRadius Health, Inc.2,400
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of FractureOsteoporosis in postmenopausal womenMedDRA version: 14.1Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-022576-30-EERadius Health, Inc.2,400